Redeye returns with an update following Alligator Bioscience’s Q1 earnings release. The report was uneventful, as expected for a pre-revenue biotech company. Costs continued trending downwards in line with our expectations. We adjust our financing assumptions while lowering our WACC. Our fair value range of SEK0-1.7, with a base case of SEK0.3, is reiterated.
